Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hormonal therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,582 result(s) found for: Hormonal therapy. Displaying page 1 of 130.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-004266-40 Sponsor Protocol Number: ICORG 06-32/NSABP B-42 Start Date*: 2007-11-02
    Sponsor Name:ICORG
    Full Title: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxife...
    Medical condition: Hormone Receptor Positive Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000155-16 Sponsor Protocol Number: CROLT/02 Start Date*: 2011-10-04
    Sponsor Name:FONDAZIONE MICHELANGELO - AVANZAMENTO DELLO STUDIO E CURA DEI TUMORI
    Full Title: Modulation of response to hormonal therapy with lapatinib and/or metformin in patients with HER2-negative, ER and/or PgR positive metastatic breast cancer with progressive disease after first-line ...
    Medical condition: Female patients with HER2-negative, ER and/or PgR positive breast cancer in progression after first-line hormonal therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038604 - Reproductive system and breast disorders 10038604 Reproductive system and breast disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-001915-35 Sponsor Protocol Number: 08052017 Start Date*: 2017-09-15
    Sponsor Name:Medical University of Graz
    Full Title: GLUCOCORTICOID HIGH-DOSE VS. REPLACEMENT IN IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HYPOPHYSITIS: AN OPEN, RANDOMIZED PILOT STUDY
    Medical condition: Immune regulatory antibodies (e.g. ipilimumab, pembrolizumab and nivolumab) inhibiting immunological checkpoints are increasingly used to treat various oncological entities. Potential side effects ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-003654-15 Sponsor Protocol Number: 080314 Start Date*: 2008-09-22
    Sponsor Name:Karolinska University Hospital
    Full Title: Oral 1 mg oestradiol (E2) / 2 mg of drosperinone (DRSP) and 1 mg of oestradiol / 0.5 mg of norethisteroneacetate (NETA): effects on mammografic density and breast epithelial proliferation - an expl...
    Medical condition: The effect of hormonal treatment on mammographic density and breast epithelial proliferation in postmenopausal women.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020422 HRT LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022319-20 Sponsor Protocol Number: 24638418 Start Date*: 2011-10-13
    Sponsor Name:Odense University Hospital
    Full Title: The effect of antidepressant therapy on quality of life, physical and menthal health and cortisole metabolism in PCOS.
    Medical condition: Polycystic Ovary Syndrome, PCOS, is the most common endocrine disorder in fertile women. Insuliresistance, hirsutism, hyperandrogenemia, adipositas, high cortisole levels and infertility are freque...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-002677-24 Sponsor Protocol Number: self sponsored Start Date*: 2005-03-07
    Sponsor Name:Karolinska Institutet, Institutionen för klinisik neurovetenskap, sektion för psykiatri
    Full Title: Hormonersättningseffekt på serotoninåterupptag hos ooforektomerade kvinnor
    Medical condition: Bilateral oophorectomy and hysterectomy and a wish for hormonal replacement therapy afterwards.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004876-20 Sponsor Protocol Number: GRAV12 Start Date*: 2012-11-13
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
    Full Title: Study on the effectiveness of two different formulations of L-thyroxine compress and liquid oral solution) in pregnant patients affected with hypothyroidism.
    Medical condition: Hypothyroidism in pregnant patients
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003667-35 Sponsor Protocol Number: GBG-97-AMICA Start Date*: 2017-12-29
    Sponsor Name:GBG Forschungs GmbH
    Full Title: Anti-hormonal maintenance treatment with the CDK4/6 inhibitor Ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial
    Medical condition: HR-positive/HER2-negative metastatic breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002113-39 Sponsor Protocol Number: BAY88-8223/16298 Start Date*: 2014-10-29
    Sponsor Name:Bayer AG
    Full Title: A phase II randomized, double-blind, placebo-controlled trial of radium-223 dichloride versus placebo when administered to metastatic HER2 negative hormone receptor positive breast cancer subjects ...
    Medical condition: HER2 negative hormone receptor positive metastatic breast cancer with bone metastases treated with standard of care hormonal treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) ES (Completed) AT (Completed) NO (Completed) CZ (Completed) DK (Prematurely Ended) NL (Completed) SE (Completed) PL (Completed) FI (Completed) IE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003467-19 Sponsor Protocol Number: CLEE011A2404 Start Date*: 2016-12-08
    Sponsor Name:Novartis Pharma AG
    Full Title: COMPLEEMENT-1: An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal wo...
    Medical condition: hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) HU (Completed) BG (Completed) PT (Completed) GR (Completed) SK (Completed) IT (Completed) CZ (Completed) AT (Completed) ES (Completed) DK (Completed) NO (Completed) PL (Completed) FI (Completed) SI (Completed) RO (Ongoing) LU (Completed)
    Trial results: View results
    EudraCT Number: 2014-001185-10 Sponsor Protocol Number: 14I/Prg02 Start Date*: 2014-09-08
    Sponsor Name:IBSA Institut Biochimique SA
    Full Title: Effect of a progesterone 25 mg solution (Pleyris, IBSA Farmaceutici Italia, srl) administered by oral route compared to an oral progesterone 200 mg capsule (Prometrium, Rottapharm SpA) on the endom...
    Medical condition: hormone replacement therapy of menopause (as progestin therapy in association to estrogen replacement therapy)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10042613 - Surgical and medical procedures 10020388 Hormone replacement therapy PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004189-33 Sponsor Protocol Number: REK322442 Start Date*: 2013-11-28
    Sponsor Name:Haukeland University Hospital
    Full Title: ULTRADIAN SUBCUTANEOUS HYDROCORTISONE (USHI) INFUSION IN ADDISON’S DISEASE
    Medical condition: Addison`s disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005496-39 Sponsor Protocol Number: APHP211042 Start Date*: 2021-12-20
    Sponsor Name:
    Full Title: Prospective, randomized, double-blind, placebo controlled, multicenter study assessing the efficacy of intracavernosal Clostridium Botulinum neurotoxin type A (Xeomin®) 100U as add-on therapy to si...
    Medical condition: Erectile dysfunction
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10020381 Hormonal imbalance LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010632-18 Sponsor Protocol Number: 022009endo Start Date*: 2009-05-21
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
    Full Title: EFFECT OF ORAL OR INTRAVENOUS STEROID PROPHYLAXIS ON THE OCCURRENCE OF GRAVES’ ORBITOPATHY IN PATIENTS WITH GRAVES’ DISEASE AFTER TREATMENT WITH RADIOACTIVE IODINE
    Medical condition: Graves’ orbitopathy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004548-30 Sponsor Protocol Number: D7917C00225 (1839IL/0225) Start Date*: 2005-11-23
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase II randomised, double-blind, stratified, multi-centre trial comparing the Nolvadex 20 mg and placebo combination to the Nolvadex 20 mg and ZD1839 (IRESSA™) 250 mg combination in patients wi...
    Medical condition: Female patients aged ³18 years, pre/post menopausal with ER and/or PR positive metastatic adenocarcinoma of the breast determined by each laboratory in each centre. Patients will be stratified int...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005109-23 Sponsor Protocol Number: AWC LowE Start Date*: 2009-08-05
    Sponsor Name:Uppsala University Hospital
    Full Title: Low-Dose Hormone Therapy Initiated early after Menopause and Changes in Artery Wall Composition (AWC), as Assesssed by High-Frequency Ultrasound.
    Medical condition: Age/menopause related changes in the artery wall composition after menopause
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    9.1 10051775 Postmenopause LLT
    9.1 10020388 Hormone replacement therapy LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019237-10 Sponsor Protocol Number: FARM8MR2J7 Start Date*: 2010-10-28
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Multicenter prospective randomized open with a blinded end point (PROBE) parallel-group study on treatment with biphasic insulin BIAsp70/30 and short-acting insulin or rapid-acting analogue plus gl...
    Medical condition: DM1
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014698 SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-015059-26 Sponsor Protocol Number: 510460 Start Date*: 2010-08-19
    Sponsor Name:Actavis GmbH & Co. KG
    Full Title: Efficacy of 12 weeks oral Pentalong® on Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension Short title: CAESAR Clinical efficacy ...
    Medical condition: Woman and men suffering from heart failure NYHA II-IV and secondary pulmonary hypertension Objectives PVR improvement after a 12 week oral Pentalong® therapy in addition to standard long-term HF...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003012-27 Sponsor Protocol Number: 18062020 Start Date*: 2021-01-12
    Sponsor Name:Canisius Wilhelmina Ziekenhuis
    Full Title: Impact of peri-operative tEstosterone levels oN Functional and oncological Outcomes following RadiCal prostatEctomy
    Medical condition: Late-onset hypogonadism
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000998-23 Sponsor Protocol Number: CL1-64315-003 Start Date*: 2019-09-19
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: A Phase I/II, open label, non-randomized study to evaluate safety, tolerability, pharmacokinetics and clinical activity of S64315 in patients with locally advanced or metastatic breast cancer in co...
    Medical condition: Locally advanced or metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 08:41:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA